Understanding the transport mechanisms of BSEP to improve the prediction of DILI compounds Robbin de Kruijf Darwin College Department of Pharmacology University of Cambridge This thesis is submitted for the degree of Doctor of Philosophy September 2019 I II Ik wijd mijn thesis toe aan mijn mama en papa en aan mijn oma en opa. Zij zijn de oorsprong van mijn nieuwsgierigheid, De reden voor mijn stoerheid. III IV Declaration This thesis is the result of my own work and includes nothing which is the outcome of work done in collaboration except as declared in the Preface and specified in the text. It is not substantially the same as any that I have submitted, or, is being concurrently submitted for a degree or diploma or other qualification at the University of Cambridge or any other University or similar institution except as declared in the Preface and specified in the text. I further state that no substantial part of my thesis has already been submitted, or, is being concurrently submitted for any such degree, diploma or other qualification at the University of Cambridge or any other University or similar institution except as declared in the Preface and specified in the text. It does not exceed the prescribed word limit for the relevant Degree Committee. V VI VII Abstract Understanding the transport mechanisms of BSEP to improve the prediction of DILI compounds Robbin de Kruijf At present, Drug-Induced Liver Injury (DILI) is the most frequent cause of acute liver injury, with an incidence ranging from 0.023-1.5‰ in developed countries. DILI can be separated into two different types. Whereas intrinsic DILI concerns predictable dose-dependent hepatoxicity, idiosyncratic DILI refers to unpredictable adverse drug reactions for which there is no existing pharmacological explanation. Many prescription and over-the-counter drugs causing DILI do so in an undiscovered and idiosyncratic pattern. It is the latter that causes DILI to be the most frequent cause of safety-related drug withdrawals. This causes delays in the availability of treatments and is responsible for 20% to 40% of liver transplants and hepatic failures. While several mechanisms might be responsible for idiosyncratic DILI, a broad industry-wide consensus was reached in 2016 on the importance of the liver bile salt export pump (BSEP) and the need to test for BSEP inhibition at an early stage of drug development. An assay for BSEP-mediated bile acid transport was established to study the biochemical mechanisms of inhibition of BSEP activity by organic compounds. The four selected compounds showed competitive inhibition of taurocholate transport in Lineweaver-Burk plots but also other types of inhibition in Eadie-Hofstee plots. These results indicate that these inhibitors might compete with taurocholate for binding in the substrate-binding pocket and possibly, that the inhibitors are transported by BSEP. Interestingly, this work shows a strong inhibitory effect of excess Mg2+ on the ability of BSEP to transport glycocholic acid; the transport of taurocholic acid was not inhibited by Mg2+. To get more insight in structure- function relationships in BSEP, a condense and accurate database of all known BSEP point mutations from published literature was compiled. This database shows a total of 264 known mutations associated with several pathogenic and non-pathogenic phenotypes. To date, there is still little known about the effects of many of these mutations on BSEP activity. Only 82 of the 264 mutations have currently been investigated for their impact on function and expression level of BSEP. VIII 2D and 3D primary cultured hepatocytes were used to establish the effect of DILI-inducing drugs on the synthesis of bile acids and their distribution across the cell and the media. Multivariate analyses of the data demonstrate that drugs can change the bile acid composition in hepatocytes and their environment. This might occur by regulating bile acid synthesis pathways and/or by modulating the selectivity of BSEP itself. Interestingly, some of the detected changes in bile acid concentrations might be early indicators of cell stress and cell death. The experiments also suggest that drugs can cause a change in BSEP expression in the plasma membrane, through changes in the trafficking of protein to and from the plasma membrane. These changes could explain the existence of non-pathogenic BSEP inhibitors. These findings increase our understanding of the influence of compounds on bile acid production and BSEP distribution and their potential roles in idiosyncratic DILI. IX Acknowledgements I wish to thank everyone who has accompanied me on this journey. I would like to express my deep gratitude to Rik, for his valuable and constructive suggestions during the planning, development and execution of the project, for his guidance and enthusiastic encouragement during the years here at Cambridge. Next, I would like to say thank you to my lab mates Lisa, Himansha, David, and Charlotte for not only being my lab mates but for also being my friends and confidantes and ear when things went wrong and were not working, and for providing feedback and for all the memories. In short for making the workplace so much better and making it a joy to come to the lab every day. With a special shout out to Lisa and Himansha, for pulling me out when I went under and for putting me right when I was simply wrong. A special thank you goes to the DMS team at AstraZeneca, under the guidance of Dominic, Alison, Katie, Sophie and Helen. I am incredibly grateful to them for teaching me new techniques providing me with constructive feedback and having me present so often (those were invaluable for the writing process of this thesis). I am grateful for AstraZeneca’s financial support during my PhD. Because of you I was able to experience the best of pharmaceutical industry. I would also like to express my gratitude to the MRC Toxicology Unit in Leicester for awarding the Integrative-Toxicology Training Partnership (ITTP) PhD studentship. I thoroughly enjoyed the yearly ITTP training weeks. Thank you to all the friends I made in Darwin, to Elaine, Meltem and Brenda. For adopting me to have a social life, for the emotional support, for helping me with statistical questions. To the rest of Darwin that taught me that I was not the only one anxious and suffering from imposter syndrome, that I was not alone with my problems. Mijn vrienden van de basisschool en van de middelbare, jullie zijn fantastisch. X To all my friends and family away from home, I’d like to say please look up “vriend” by Toon Hermans. His poem describes much better what I feel about you all. You all make me realise how blessed I really am. Schließlich meine Familie, meine Brüder die immer meine Brüder gewesen sind. Ab und zu seid ihr Idioten und Clowns aber die meiste Zeit weiß ich das ich immer auf euch zählen kann. Ob es mitten in der Nacht ist oder auf der anderen Seite der Welt. Uiteindelijk zou ik graag mijn tante willen bedanken. Woorden zijn hier niet genoeg, maar ik hoop dat zij weet hoeveel haar liefde, haar ondersteuning, haar optimisme, haar hardnekkigheid en haar pragmatisme voor mij betekenen. Zij is een grote inspiratie voor mij, en zonder haar zou ik nooit, maar dan ook echt nooit, zover gekomen zou zijn. Ik noem haar misschien niet mama, maar mama is alleen een word, alle gevoelens die erbij horen zijn voor mij geassocieerd met “Agnes”. There are so many people I’d like to thank, so many memories I treasure and initially I wanted to put a picture collage of all my memories in here but thought the better of it. Still I made a collage for myself with all the pictures I gathered and put it in my own copy. Thank You, Thank you so much XI List of Abbreviations and Acronyms 2D 2 dimensional (sandwich culture) 3D 3 dimensional (spheroid culture) ABC transporter ATP binding cassette transporter ABCB1 ATP binding cassette subfamily B member 1 ABCB11 ATP binding cassette subfamily B member 11 AKR1C4 aldo-keto reductase family 1 member C4 AKR1D1 aldo-keto reductase family 1 member D1 AKT AKT serine/threonine Kinase AMACR alpha-methylacyl-CoA racemase aMCA alpha-muricholic acid AMP adenosine monophosphate ASBT apical sodium-dependent bile acid transporter ATP adenosine triphosphate AZ Astrazeneca BAAT bile acid-CoA:amino acid N-acyltransferase BCOX acyl-CoA oxidase 2 bMCA beta-muricholic acid BRIC2 benign recurrent intrahepatic cholestasis type 2 BS bosentan treatment BSA bovine serum albumin BSEP bile salt export pump CA cholic acid cAMP cyclic adenosine monophosphate CDCA chenodeoxycholic acid CH cyclohexamide treatment CP clobetasol propionate treatment CVB covalent binding burden Cyp27A1 cytochrome P450 family 27 subfamily A member 1 DCA deoxycholic acid DILI Drug-induced liver injury DM DMSO treatment DMSO dimethyl sulfo-oxide DNA deoxyribonucleic acid DPBS dulbecco's phosphate buffered saline E.Coli Escherichia coli EDTA ethylenediaminetetraacetic acid EGTA ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid EMA European Medicines Agency ES estradiol treatment FCS/FBS fetal calf serum/fetal bovine serum FDA U.S. Food and Drug Administration FXR farnesoid X nuclear receptor GCA glycocholic acid XII GCDCA glycochenodeoxycholic acid GDCA glycodeoxycholic acid GUDCA glycoursodeoxycholic acid hBSEP human bile salt export pump IC50 Half-maximal inhibitory concentration ICH International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use iDILI idiosyncratic drug-induced liver injury IHC intrahepatic